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Abstract 
Objectives: To measure awareness about adverse drug reaction (ADRs) reporting among doctors, pharmacists and 
nurses and to determine reasons of ADRs under‑reporting in Pakistan.
Methods: In present study, a self‑administered questionnaire was used to measure the awareness level about ADRs 
reporting among health care professionals (HCPs) of Pakistan. This was a cross sectional study.
Results: Out of the respondents 51 % were physicians, 29.7 % pharmacists and 19.3 % were nurses. 65.5 % of HCP 
population observed ADRs, out of which only 57.4 % reported these in their respective hospitals. About 77.3 % of 
population understood the importance of reporting ADRs while 67.3 % of population agrees that pharmacists are 
chief personnel for the development of system. 71.8 % of HCPs agrees that ADRs are not reported because Commu‑
nity pharmacy lacks legally qualified pharmacists. Only 14.3 % of HCPs population knows that there is any ADR report‑
ing organization in Pakistan.
Conclusion: The study recommends the need of such reporting system and more than half of the studied popula‑
tion agreed that pharmacists are required in developing such system.
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Background
As per definition of Pharmacovigilance (PV) it is not 
only science but also actions which are for the detec-
tion, assessment, understanding and prevention of 
adverse effects or any other drug-related problem. The 
Thalidomide disaster in 1961 was the start of establish-
ing the WHO Program for International Drug Monitor-
ing, WHO promotes PV at the country level by working 
in collaboration with the Monitoring centre at Uppsala. 
More than 135 countries are the part of this program. 
This program not only enhances patient safety for use of 
medicines but also gives information about safe use and 
prevention and treatment of any Adverse Drug Reac-
tions (ADRs) (http://www.who.int/medicines/areas/
quality_safety/safety_efficacy/pharmvigi/en/).
WHO’s definition of ADRs, which has been in use for 
about 30 years, is “a response to a drug that is noxious and 
unintended and occurs at doses normally used in man for 
the prophylaxis, diagnosis or therapy of disease, or for 
modification of physiological function” (WHO 1972).
The birth defects were caused by thalidomide in 1961–
1962 in about ten thousand children in different regions 
of the world, when the pregnant mothers used it for nau-
sea and vomiting. As a result in 1968 the WHO started 
the Program for International Drug Monitoring (PIDM) 
for early detection of ADRs. This activity is now called as 
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Pharmacovigilance. Uppsala Monitoring Centre (UMC) 
in Sweden is responsible to monitor and manage the 
WHO-PIDM activities (Collet 2000; Blenkinsopp et  al. 
2007; Gregg and Stuart 2010).
The inclination should be there to not only observe but 
also report unwanted and unexpected medical events in 
all areas where medicines are being used. At any dosage 
and by an overdose or by misuse or abuse of a medicine 
the adverse drug reactions or adverse events can occur 
(WHO 2002a). Pharmacovigilance is applied throughout 
the life cycle of a medicine that is from the pre-approval 
phase to the end use by the patients. These lead to bur-
den on patients not only in disease form by prolonged 
stay in hospital but also the financial burden it creates 
immensely (Johnson and Bootman 1997). Pharma-
covigilance focuses on not only effectiveness and ben-
efits but also on safety and risk analysis with the aim to 
improve patient care (Cipolle et al. 2004; www.fda.com). 
The safety of patients is totally related with the safety of 
medicines. ADR monitoring is an integral part of quality 
assurance department in developed countries but unfor-
tunately Pakistan has limited accountability system for 
medicines (Scurti et al. 2012; Rollins 2013).
Healthcare systems rely mainly on the detection and 
reporting of suspected ADRs to identify new reactions, 
record the frequency with which they are reported, eval-
uate factors that may increase risk and provide informa-
tion to prescribers with a view to preventing future ADRs, 
shows that adverse drug reaction are by anyway causing 
deaths (Collet 2000). The actual statistics of ADR related 
death in Pakistan is not available because of underdevel-
opment of such system throughout Pakistan few of the 
hospitals like AGHA KHAN and DOW UNIVERSITY 
HOSPITAL practices reporting at their own level but sys-
tem in just a few health care sectors in a large popula-
tion is not sufficient obviously. Efforts are increasing to 
ensure that resource poor countries, which bear almost 
90 % of the global disease burden, have access to effective 
medicines (Mahmood et  al. 2011). Pakistan Pharmacist 
Federation has launched a campaign to implement the 
directions of Health Department, Government of Punjab, 
Pakistan to establish pharmacovigilance centre, adverse 
drug reporting, drug information and poison control 
centre at provincial and hospital level (Davies et al. 2009). 
Medication errors are usually not reported for the rea-
son that the errors are considered as not very much sig-
nificant by the prescriber that they should be reported 
(www.pharmacistfed.wordpress.com). Under reporting 
of ADRs influenced by prescriber’s and reporter’s medi-
cal knowledge and their approach to give significance to 
any types of ADR. This under reporting creates a nega-
tive impact on Public Health (Pirmohamed et al. 2007).
The purpose of the study is to evaluate the knowledge 
and concerns of the health care professionals about 
adverse drug reaction and its reporting which claims 
the development and incorporation of system including 
adverse drug reaction reporting and training to health 
care professionals about detection, assessment and con-
trol adverse drug reaction. Even though in countries like 
UK where pharmacovigilance activities are being prac-
ticed, the occurrence rate of ADR is 6.7  % with overall 
fatality rate is 0.32 % (Kazeem and Jacob 2009). Our study 
acknowledges the importance of ADR reporting and 
steps must be taken at national level to ensure the incor-




A cross sectional study was conducted from June, 2013 to 
August, 2014 in Karachi, a metropolitan city of Pakistan. 
Target responders consisted of different health care pro-
fessionals including nurses, pharmacist and physicians/
doctors working in different health care services of the 
city.
The questionnaire being addressed was adapted from 
studies regarding concerns of health care professionals 
about adverse drug reaction reporting and reasons of 
underreporting these reactions, information and knowl-
edge about reporting of ADR. Health care profession-
als mostly addressed were physicians, pharmacists and 
nurses working at public sector hospitals. (WHO Pro-
gram for International Drug Monitoring 2010)
Institutional Research Review Committee has approved 
this study and has found it exempted from any IRB.
Sample size
At 99 % confidence interval with 5 % bound of error of 
unawareness rate of 84  % of Irish physicians (Williams 
and Feely 1999). The calculated sample size was 357 
HCPs which was calculated by the population size of 
HCPs in Karachi, Pakistan.
Study population
According to sample size calculated 357 questionnaire 
forms were distributed to health care professionals of dif-
ferent Tertiary Health Care sectors of Karachi, including 
Dow University Hospital, Civil Hospital, Abbasi Shaheed 
Hospital, Liaquat National Hospital, Orthopedics and 
Medical Institute, Patel Hospital. Questionnaire forms 
were self addressed to HCPs.Of the respondents 51  % 
were physicians including house officers, RMO’s, sur-
geons, consultant doctors, and 29.7  % were pharmacist 
working at inpatient pharmacy services and 19.3 % nurses.
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Statistical analysis
Data were analyzed using Statistical Package for Social 
Sciences (SPSS) version 21. Descriptive statistics were 
employed to report the response of respondents in terms 
of frequency and percentage. Since, responses were ordi-
nal scaled, therefore, gradient effect Chi-square test was 
executed to measure association of knowledge, attitude, 
perception, practices and reasons of non-compliance 
with different HCPs. P value less than 0.05 was consid-
ered to show significant association.
Results
A total of 357 responses were compiled in the data file. 
Out of the respondents 51 % (n = 182) were physicians, 
29.7 % (n = 106) were pharmacists and 19.3 % (n = 69) 
were nurses. The findings depicted only 43.4 % (n = 155) 
HCPs knew the term Pharmacovigilance and ADR 
reporting. The frequency of knowledge of term Phar-
macovigilance was significantly more among pharma-
cists followed by physicians (P < 0.0001). Only 31.7 % of 
respondents know that there is any ADR reporting form 
at the website of Drug Regulatory Authority of Pakistan 
(DRAP) while DRAP is established since 2012. Phar-
macist followed by nurses confirmed the knowledge 
of DRAP webpage significantly more than physicians 
(P = 0.017). Furthermore only 14.3 % of HCPs respond-
ents knows that there is any ADR reporting organization 
in Pakistan. Though, the linear association of the knowl-
edge of ADR reporting organization in Pakistan was not 
significant showing similar knowledge among three types 
of HCPs (Table 1) indicating that there is a problem about 
national reporting in Pakistan across all the professionals.
About 67.3  % of respondents agreed that pharma-
cists are chief personnel for the development of system 
(Table 2). The agreement of relating pharmacists as chief 
personnel for reporting ADR was proportionally least 
among physicians followed by nurses (P =  0.0002). The 
proportion of agreement to collaborate pharmacist with 
other HCPs was high among pharmacist. The require-
ment of drug utilization review and ADR reporting 
system is highly acknowledged by all three health care 
professionals (P = 0.308).
About 77.3  % of respondents understood the impor-
tance of reporting ADRs. Though, only 38.9 % confessed 
presence of ADR reporting system in their respective 
health care system (Table  3). There was no significant 
association of owning the responsibility of ADR report-
ing among these three professionals. While asking about 
presence of ADR reporting system in respective health 
care setup, the proportion of denying the same was sig-
nificantly higher from physicians, followed by pharma-
cists (P < 0.0001).
Nearly half percent (n = 186) HCPs were found to be 
trained for detecting, reporting and controlling ADR. The 
Table 1 Knowledge about ADR reporting from three different HCPs
Designation P value
Physician Pharmacist Nurse
N % N % N %
I know the term pharmacovigilence and ADR reporting
 Strongly disagree 7 3.8 0 0.0 0 0.0 <0.0001
 Disagree 10 5.5 0 0.0 3 4.3
 Neutral 116 63.7 29 27.4 37 53.6
 Agree 33 18.1 31 29.2 26 37.7
 Strongly agree 16 8.8 46 43.4 3 4.3
I know that there is a form for ADR reporting available at ministry of health (DRAP) website
 Strongly disagree 25 13.7 2 1.9 10 14.5 0.017
 Disagree 83 45.6 23 21.7 26 37.7
 Neutral 37 20.3 22 20.8 16 23.2
 Agree 25 13.7 38 35.8 13 18.8
 Strongly agree 12 6.6 21 19.8 4 5.8
I know the ADR reporting organization where I can report, in pakistan
 Strongly disagree 12 6.6 1 0.9 5 7.2 0.937
 Disagree 32 17.6 26 24.5 21 30.4
 Neutral 122 67.0 51 48.1 36 52.2
 Agree 9 4.9 11 10.4 5 7.2
 Strongly agree 7 3.8 17 16.0 2 2.9
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training of detection and reporting of ADR was found 
significantly more among nurses (P  =  0.006). Around 
65.5 % of HCP respondents observed ADR whereas only 
57.4 % report these in their respective hospitals. Obser-
vation of ADR was significantly not different among 
these three HCPs. Though, reporting the same was found 
significantly least among physicians followed by nurses 
(P  =  0.001). Reporting of ADR to any pharmaceutical 
industry was not in higher proportion (Table 4).
Furthermore, our study also highlighted various rea-
sons of underreporting. HCPs (84.6 %) have uncertainty 
whether the ADRs occurred due to drugs, unavailability 
of reporting forms (e.g. yellow cards), 71.8  % of HCPs 
agrees that ADRs are not reported because Community 
Table 2 Attitude for ADR reporting from three different HCPs
Designation P value
Physician Pharmacist Nurse
N % N % N %
Pharmacists are the cheif personel required for ADR reporting system development
 Strongly disagree 14 7.7 2 1.9 0 0.0 0.002
 Disagree 22 12.1 8 7.5 8 11.6
 Neutral 37 20.3 11 10.4 15 21.7
 Agree 75 41.2 43 40.6 25 36.2
 Strongly agree 34 18.7 42 39.6 21 30.4
Other health care professionals must be in collaboration of pharmacists, physicians and nurses
 Strongly disagree 4 2.2 0 0.0 1 1.4 0.068
 Disagree 13 7.1 2 1.9 4 5.8
 Neutral 24 13.2 7 6.6 7 10.1
 Agree 90 49.5 43 40.6 37 53.6
 Strongly agree 51 28.0 54 50.9 20 29.0
Drug utilization review and ADR reporting system is required in our hospitals to reduce adverse drug events
 Strongly disagree 6 3.3 1 0.9 0 0.0 0.308
 Disagree 9 4.9 1 0.9 4 5.8
 Neutral 39 21.4 9 8.5 19 27.5
 Agree 84 46.2 47 44.3 33 47.8
 Strongly agree 44 24.2 48 45.3 13 18.8
Table 3 Perception about ADR reporting from three different HCPs
Designation P value
Physician Pharmacist Nurse
N % N % N %
ADR reporting is my responsiblity
 Strongly disagree 6 3.3 2 1.9 1 1.4 0.986
 Disagree 18 9.9 3 2.8 9 13.0
 Neutral 24 13.2 6 5.7 12 17.4
 Agree 78 42.9 38 35.8 35 50.7
 Strongly agree 56 30.8 57 53.8 12 17.4
ADR reporting system is present in my health care sector setup
 Strongly disagree 39 21.4 3 2.8 5 7.2 <0.0001
 Disagree 25 13.7 16 15.1 7 10.1
 Neutral 73 40.1 32 30.2 18 26.1
 Agree 15 8.2 28 26.4 22 31.9
 Strongly agree 30 16.5 27 25.5 17 24.6
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pharmacy lacks legally qualified pharmacists (Table  5). 
Physicians were significantly least agreed of ADR under-
reporting due to shortage of time (P =  0.013), compla-
cency (P  =  0.011) and belief of safe marketed drugs 
(P = 0.006).
Discussion
Because of a counterfeit antihypertensive medicine 
at the  Punjab Institute of Cardiology (PIC) hospital at 
Lahore, Pakistan, the lives of over 100 heart patients were 
taken away in January 2012 (Kazeem and Jacob 2009). 
The counterfeit medicine(s) deposited in the bone mar-
row of patients and lost the patient’s resistances. The 
drug caused the suppression of generation of white blood 
cells after being deposited in bone marrow. Which lead 
to change in skin pigmentation, severe chest infection, 
decreased platelet count and blood vomiting (Thenews.
com.pk 2012).
As it has been reported that the infer drugs include 
isotab (isosorbide nitrate), lipitor (atorvastatin calcium), 
soloprin (aspirin), cardiovestin (simvastatin), concort 
(amlodipine), and alfagril (clopidogrel) (Desk 2012).
Import of medicines from Pakistan was banned by Sri 
Lanka as a precautionary measure (Usman 2012). As 
a consequence, Efroze Pharma was called by the WHO 
for increased vigilance on the use of isotab, for which it 
released a global drug safety alert (no. 125) (Wasif 2012).
Considering the importance of ADRs reporting, our 
study showed inadequate knowledge of physician and 
nurses about an adverse drug reaction and reporting. 
Study also reveals the point of enhancing awareness 
among the HCPs also increase in DRAP’s role for this 
purpose. (WHO 2002b)
Doctors, pharmacists and nurses as well as patients can 
report ADRs. This may become more rapid and advanced 
by the use of new softwares and internet. The way in 
which companies and governments handle patients data 
may become safe by law now is passed by the mem-
ber states will enable the security and privacy of patient 
data (The News Tribe 2012; MedWatch 2015; Chanda 
Table 4 Practices for ADR reporting from three different HCPs
Practices Designation P value
Physician Pharmacist Nurse
N % N % N %
I am trained to detect, report and control ADR
 Strongly disagree 14 7.7 2 1.9 2 2.9 0.006
 Disagree 57 31.3 12 11.3 11 15.9
 Neutral 35 19.2 20 18.9 18 26.1
 Agree 45 24.7 46 43.4 34 49.3
 Strongly agree 31 17.0 26 24.5 4 5.8
I have observed ADR
 Strongly disagree 11 6.0 1 0.9 1 1.4 0.29
 Disagree 32 17.6 7 6.6 12 17.4
 Neutral 27 14.8 19 17.9 13 18.8
 Agree 71 39.0 39 36.8 34 49.3
 Strongly agree 41 22.5 40 37.7 9 13.0
I report ADR in my health care sector
 Strongly disagree 6 3.3 2 1.9 2 2.9 0.001
 Disagree 52 28.6 9 8.5 4 5.8
 Neutral 35 19.2 25 23.6 17 24.6
 Agree 57 31.3 44 41.5 34 49.3
 Strongly agree 32 17.6 26 24.5 12 17.4
I report ADR in any pharmaceutical industry
 Strongly disagree 18 9.9 9 8.5 8 11.6 0.17
 Disagree 85 46.7 44 41.5 23 33.3
 Neutral 46 25.3 24 22.6 22 31.9
 Agree 30 16.5 26 24.5 15 21.7
 Strongly agree 3 1.6 3 2.8 1 1.4
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Table 5 Reasons for ADR misreporting from three different HCPs
Reasons Designation P value
Physician Pharmacist Nurse
N % N % N %
ADR reporting system not incorporated because of limited awareness of the health care professionals
 Strongly disagree 7 3.8 0 0.0 1 1.4 0.515
 Disagree 16 8.8 8 7.5 12 17.4
 Neutral 42 23.1 11 10.4 22 31.9
 Agree 76 41.8 49 46.2 23 33.3
 Strongly agree 41 22.5 38 35.8 11 15.9
ADR reporting system not incorporating in Karachi Hospitals because of financial issues
 Strongly disagree 10 5.5 2 1.9 3 4.3 0.982
 Disagree 37 20.3 18 17.0 14 20.3
 Neutral 46 25.3 26 24.5 17 24.6
 Agree 58 31.9 44 41.5 30 43.5
 Strongly agree 31 17.0 16 15.1 5 7.2
ADR’s not reported because of shortage of time
 Strongly disagree 10 5.5 2 1.9 1 1.4 0.013
 Disagree 49 26.9 21 19.8 13 18.8
 Neutral 40 22.0 14 13.2 17 24.6
 Agree 56 30.8 42 39.6 25 36.2
 Strongly agree 27 14.8 27 25.5 13 18.8
ADR’s not reported because of unavailiblity of reporting forms
 Strongly disagree 8 4.4 1 0.9 0 0.0 0.517
 Disagree 26 14.3 22 20.8 11 15.9
 Neutral 40 22.0 19 17.9 17 24.6
 Agree 84 46.2 50 47.2 30 43.5
 Strongly agree 24 13.2 14 13.2 11 15.9
ADR’s not reported because complacency (uncertinity that ADR occurred due to drug administered)
 Strongly disagree 4 2.2 3 2.8 0 0.0 0.011
 Disagree 22 12.1 14 13.2 7 10.1
 Neutral 127 69.8 44 41.5 44 63.8
 Agree 22 12.1 34 32.1 12 17.4
 Strongly agree 7 3.8 11 10.4 6 8.7
ADR’s not reported because of the belief that all marketted drugs are safe
 Strongly disagree 13 7.1 15 14.2 1 1.4 0.006
 Disagree 35 19.2 27 25.5 14 20.3
 Neutral 122 67.0 48 45.3 35 50.7
 Agree 12 6.6 10 9.4 13 18.8
 Strongly agree 0 0.0 6 5.7 6 8.7
Community pharmacy (medical stores) lacking legally qualified pharmacist causing non reporting
 Strongly disagree 7 3.8 3 2.8 0 0.0 0.243
 Disagree 26 14.3 1 0.9 7 10.1
 Neutral 27 14.8 13 12.3 17 24.6
 Agree 60 33.0 30 28.3 28 40.6
 Strongly agree 62 34.1 59 55.7 17 24.6
Fatal ADR’s are mostly not reported because usually general public donot allow conducting postmartem studies
 Strongly disagree 5 2.7 0 0.0 0 0.0 0.721
 Disagree 20 11.0 4 3.8 3 4.3
 Neutral 24 13.2 18 17.0 18 26.1
 Agree 75 41.2 46 43.4 34 49.3
 Strongly agree 58 31.9 38 35.8 14 20.3
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2007; Strengthening Pharmaceutical Systems (SPS) 2009; 
Cobert and Silvey 1999).
Because of absence of appropriate clinical trials in the 
paediatric population, drugs prescription in children has 
a high risk of developing unknown or rare adverse drug 
reactions (ADRs). The spontaneous reporting of sus-
pected ADRs is an important way to promote reasonable 
warning signals. The family paediatricians (FPs) play a 
crucial role in this reporting (http://www.isoponline.org).
Pharmacists can be the chief personnel for the develop-
ment of Pharmacovigilance system as 59.89 % (n = 109) 
Physicians, 66.66 % (n = 46) nurses and 80.1 % (n = 85) 
Pharmacists agrees upon the point. In 60.1  % of HCPs 
opinion there is no any Pharmacovigilance system exists 
in their respective health care sectors.
As per study results, HCPs observe ADRs during their 
clinical practice but the reporting of those ADRs are 
very much limited to the concerning authorities whether 
Pharmaceutical Industry or Government concerned 
department (Khurshid et al. 2008).
Furthermore, study reveals the reasons that could be 
looked into for the betterment of reporting of ADRs. 
According to the study, reasons mainly causing under-
reporting of ADR’s are, Uncertainty of whether ADRs 
occur due to drug or not, community pharmacy lack-
ing legally qualified pharmacist, Unavailability of ADR 
reporting form (e.g. Yellow cards), and awareness 
regarding system (Pellegrino et al. 2013). Financial issues 
can be resolved if the steps are taken at governmental 
level. Physicians generally are not very much responsive 
to ADR reporting program mainly because of the time 
that they prefer to reserve for patients rather to spare 
time for reporting (Table 5). Other reasons also contrib-
utes but to a lesser extent in underreporting of ADRs 
(WHO 2002b).
Study also force on the point of having Drug Utilization 
Review or ADR reporting system within the Health Care 
Sectors to reduce the rate of adverse drug events (http://
www.who-umc.org).
Incorporation of pharmacists in health care sectors for 
making policies regarding the system and acceptability 
among other health care professionals for the pharma-
cists to detect report and control ADRs is necessary. As 
has been mentioned that physicians are not very coop-
erative to report ADRs so, to increase reporting many 
countries allowed pharmacists working in hospital and 
community, nurses and even patients to report ADR 
(Olsson 1998).
There is also presence of nurses throughout in all hos-
pitals especially in public sectors hospitals who even do 
not know about the presence of such reactions even most 
of the At least 60 % of ADRs are preventable (http://www.
isoponline.org).
Medical practitioners are the primary component of 
ADR reporting system but every healthcare professional 
who is having knowledge, attitudes and perceptions 
about ADR can play its part in reporting ADRs (Khurs-
hid et al. 2008). As 77.47 % (n = 141) Physicians, 82.01 % 
(n = 57) nurses and 91.51 % (n = 97) pharmacists agrees 
upon the point (Table 2).
Conclusion
Adverse drug events are preventable most of the time. 
Even then it is reported to be the 8th-leading cause of 
death which exceeds the deaths attributable to motor 
vehicle accidents, breast cancer or AIDS (Shin et  al. 
2011). These results shows that even in developed coun-
try where expertise are practicing such system, the ADR 
related deaths are a matter of serious concerns.
Pharmacovigilance system implementation is the 
need which is possible by collaboration between aca-
demia, health care providers including pharmacist, 
patient, manufacturer, government, media, and civil 
society, Uppsala Monitoring Center (UMC), Swe-
den operating under (WHO), FDA, Isop and other 
international organization working on drug safety. 
To enhance the patients trust it is great opportunity 
for Pharmacists to built Pharmacovigilance system in 
Pakistan (http://www.ppma.org.pk/PPMAIndustry.
aspx). Reporting of any doubtful ADR event by health 
care professional is of concern because seemingly the 
relationship between the medicine and its reaction is 
not very much clear but analysis after reporting can 
evaluate its importance. Further, such PVsystem on 
national level can work with help of coordinator and a 
core committee to make plans and to take decision for 
the national centre to maintain the quality (National 
Health Policy 2001). Focus group interviews can be 
beneficial retrieving the reasons of underreporting 
than deliberately action upon them can lead to appro-
priate reporting leading to better patient health care 
(http://www.dcomoh.gov.pk/). Fear of reaction from 
the nurse managers and coworkers, fear of termina-
tion from job are found to be the reasons of underre-
porting of medication errors by nurses. With the help 
of continuous medical education programs the nurses 
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